Predictors of late virologic failure after initial successful suppression of HIV replication on efavirenz-based antiretroviral therapy

ACTG A5175/PEARLS Study Team

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Practical issues, including cost, hinder implementing virologic monitoring of patients on antiretroviral therapy (ART) in resource-limited settings. We evaluated factors that might guide monitoring frequency and efforts to prevent treatment failure after initial virologic suppression. Methods: Participants were the 911 HIV-infected antiretroviral-naïve adults with CD4 count <300 cells/μL who started efavirenz-based ART in the international A5175/PEARLS trial and achieved HIV-1 RNA <1000 copies/mL at 24 weeks. Participant report of ART adherence was evaluated using a structured questionnaire in monthly interviews. Adherence and readily available clinical and laboratory measures were evaluated as predictors of late virologic failure (late VF: confirmed HIV-1 RNA ≥1000 copies/mL after 24 weeks). Results: During median follow-up of 3.5 years, 82/911 participants (9%) experienced late VF. Of 516 participants reporting missed doses during the first 24 weeks of ART, 55 (11%) experienced late VF, compared with 27 (7%) of 395 participants reporting no missed doses (hazard ratio: 1.73; 95% CI: 1.08, 2.73). This difference persisted in multivariable analysis, in which lower pre-ART hemoglobin and absence of Grade ≥3 laboratory results prior to week 24 were also associated with higher risk of late VF. Discussion: In this clinical trial, the late VF rate after successful suppression was very low. If achievable in routine clinical practice, virologic monitoring involving infrequent (e.g. annual) measurements might be considered; the implications of this for development of resistance need evaluating. Patients reporting missed doses early after ART initiation, despite achieving initial suppression, might require more frequent measurement and/or strategies for promoting adherence.

Original languageEnglish (US)
Pages (from-to)173-180
Number of pages8
JournalHIV Clinical Trials
Volume17
Issue number5
DOIs
StatePublished - Sep 2 2016

Fingerprint

efavirenz
HIV
HIV-1
Therapeutics
Physiologic Monitoring
CD4 Lymphocyte Count
Treatment Failure
Hemoglobins
Clinical Trials
RNA
Interviews

Keywords

  • Adherence
  • Antiretroviral therapy
  • Resource-limited settings
  • Viral load monitoring
  • Virologic failure
  • Virologic suppression

ASJC Scopus subject areas

  • Medicine(all)
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Predictors of late virologic failure after initial successful suppression of HIV replication on efavirenz-based antiretroviral therapy. / ACTG A5175/PEARLS Study Team.

In: HIV Clinical Trials, Vol. 17, No. 5, 02.09.2016, p. 173-180.

Research output: Contribution to journalArticle

@article{08c6fb74c3144fa5b79d9640387c6058,
title = "Predictors of late virologic failure after initial successful suppression of HIV replication on efavirenz-based antiretroviral therapy",
abstract = "Background: Practical issues, including cost, hinder implementing virologic monitoring of patients on antiretroviral therapy (ART) in resource-limited settings. We evaluated factors that might guide monitoring frequency and efforts to prevent treatment failure after initial virologic suppression. Methods: Participants were the 911 HIV-infected antiretroviral-na{\"i}ve adults with CD4 count <300 cells/μL who started efavirenz-based ART in the international A5175/PEARLS trial and achieved HIV-1 RNA <1000 copies/mL at 24 weeks. Participant report of ART adherence was evaluated using a structured questionnaire in monthly interviews. Adherence and readily available clinical and laboratory measures were evaluated as predictors of late virologic failure (late VF: confirmed HIV-1 RNA ≥1000 copies/mL after 24 weeks). Results: During median follow-up of 3.5 years, 82/911 participants (9{\%}) experienced late VF. Of 516 participants reporting missed doses during the first 24 weeks of ART, 55 (11{\%}) experienced late VF, compared with 27 (7{\%}) of 395 participants reporting no missed doses (hazard ratio: 1.73; 95{\%} CI: 1.08, 2.73). This difference persisted in multivariable analysis, in which lower pre-ART hemoglobin and absence of Grade ≥3 laboratory results prior to week 24 were also associated with higher risk of late VF. Discussion: In this clinical trial, the late VF rate after successful suppression was very low. If achievable in routine clinical practice, virologic monitoring involving infrequent (e.g. annual) measurements might be considered; the implications of this for development of resistance need evaluating. Patients reporting missed doses early after ART initiation, despite achieving initial suppression, might require more frequent measurement and/or strategies for promoting adherence.",
keywords = "Adherence, Antiretroviral therapy, Resource-limited settings, Viral load monitoring, Virologic failure, Virologic suppression",
author = "{ACTG A5175/PEARLS Study Team} and Isaac Singini and Campbell, {Thomas B.} and Smeaton, {Laura M.} and Nagalingeswaran Kumarasamy and {La Rosa}, Alberto and Sineenart Taejareonkul and Steven Safren and Flanigan, {Timothy P.} and Hakim, {James G.} and Hughes, {Michael D.}",
year = "2016",
month = "9",
day = "2",
doi = "10.1080/15284336.2016.1201300",
language = "English (US)",
volume = "17",
pages = "173--180",
journal = "HIV Clinical Trials",
issn = "1528-4336",
publisher = "Thomas Land Publishers Inc.",
number = "5",

}

TY - JOUR

T1 - Predictors of late virologic failure after initial successful suppression of HIV replication on efavirenz-based antiretroviral therapy

AU - ACTG A5175/PEARLS Study Team

AU - Singini, Isaac

AU - Campbell, Thomas B.

AU - Smeaton, Laura M.

AU - Kumarasamy, Nagalingeswaran

AU - La Rosa, Alberto

AU - Taejareonkul, Sineenart

AU - Safren, Steven

AU - Flanigan, Timothy P.

AU - Hakim, James G.

AU - Hughes, Michael D.

PY - 2016/9/2

Y1 - 2016/9/2

N2 - Background: Practical issues, including cost, hinder implementing virologic monitoring of patients on antiretroviral therapy (ART) in resource-limited settings. We evaluated factors that might guide monitoring frequency and efforts to prevent treatment failure after initial virologic suppression. Methods: Participants were the 911 HIV-infected antiretroviral-naïve adults with CD4 count <300 cells/μL who started efavirenz-based ART in the international A5175/PEARLS trial and achieved HIV-1 RNA <1000 copies/mL at 24 weeks. Participant report of ART adherence was evaluated using a structured questionnaire in monthly interviews. Adherence and readily available clinical and laboratory measures were evaluated as predictors of late virologic failure (late VF: confirmed HIV-1 RNA ≥1000 copies/mL after 24 weeks). Results: During median follow-up of 3.5 years, 82/911 participants (9%) experienced late VF. Of 516 participants reporting missed doses during the first 24 weeks of ART, 55 (11%) experienced late VF, compared with 27 (7%) of 395 participants reporting no missed doses (hazard ratio: 1.73; 95% CI: 1.08, 2.73). This difference persisted in multivariable analysis, in which lower pre-ART hemoglobin and absence of Grade ≥3 laboratory results prior to week 24 were also associated with higher risk of late VF. Discussion: In this clinical trial, the late VF rate after successful suppression was very low. If achievable in routine clinical practice, virologic monitoring involving infrequent (e.g. annual) measurements might be considered; the implications of this for development of resistance need evaluating. Patients reporting missed doses early after ART initiation, despite achieving initial suppression, might require more frequent measurement and/or strategies for promoting adherence.

AB - Background: Practical issues, including cost, hinder implementing virologic monitoring of patients on antiretroviral therapy (ART) in resource-limited settings. We evaluated factors that might guide monitoring frequency and efforts to prevent treatment failure after initial virologic suppression. Methods: Participants were the 911 HIV-infected antiretroviral-naïve adults with CD4 count <300 cells/μL who started efavirenz-based ART in the international A5175/PEARLS trial and achieved HIV-1 RNA <1000 copies/mL at 24 weeks. Participant report of ART adherence was evaluated using a structured questionnaire in monthly interviews. Adherence and readily available clinical and laboratory measures were evaluated as predictors of late virologic failure (late VF: confirmed HIV-1 RNA ≥1000 copies/mL after 24 weeks). Results: During median follow-up of 3.5 years, 82/911 participants (9%) experienced late VF. Of 516 participants reporting missed doses during the first 24 weeks of ART, 55 (11%) experienced late VF, compared with 27 (7%) of 395 participants reporting no missed doses (hazard ratio: 1.73; 95% CI: 1.08, 2.73). This difference persisted in multivariable analysis, in which lower pre-ART hemoglobin and absence of Grade ≥3 laboratory results prior to week 24 were also associated with higher risk of late VF. Discussion: In this clinical trial, the late VF rate after successful suppression was very low. If achievable in routine clinical practice, virologic monitoring involving infrequent (e.g. annual) measurements might be considered; the implications of this for development of resistance need evaluating. Patients reporting missed doses early after ART initiation, despite achieving initial suppression, might require more frequent measurement and/or strategies for promoting adherence.

KW - Adherence

KW - Antiretroviral therapy

KW - Resource-limited settings

KW - Viral load monitoring

KW - Virologic failure

KW - Virologic suppression

UR - http://www.scopus.com/inward/record.url?scp=84979993844&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979993844&partnerID=8YFLogxK

U2 - 10.1080/15284336.2016.1201300

DO - 10.1080/15284336.2016.1201300

M3 - Article

AN - SCOPUS:84979993844

VL - 17

SP - 173

EP - 180

JO - HIV Clinical Trials

JF - HIV Clinical Trials

SN - 1528-4336

IS - 5

ER -